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Polymyalgia Rheumatica (PMR) was a term first used by Barber in 1957, to describe a sudden onset 
inflammatory condition typified by pain and stiffness of the shoulder and pelvic girdles associated 
with constitutional effects. The condition previously carried numerous other names, with the first 
being described by Bruce in 1888 as senile rheumatic gout. Initially, treatment with salicylates was 
suggested, with glucocorticoids (steroids) being reserved for more severe cases. Since the 1960s 
steroids have become the treatment of choice.  
In common with many conditions the ideal oral steroid regimen has not been formally tested using a 
placebo controlled, double-blind randomised trial. National guidance has been produced, with BSR 
and EULAR recommending an initial starting dose of prednisolone between 12.5 mg to 25 mg daily 
continued for two to four weeks. Following this, in patients who respond to treatment, the guidance 
recommends reducing the dose to 10 mg once daily after four to eight weeks (1, 2), with further 
reductions by 1 mg daily each month until steroids are fully withdrawn (1). This slow withdrawal 
from 10 mg daily is supported by more recent observational data and a systematic review (3). Using 
these regimens the earliest steroids are recommended to be stopped is after 44 to 50 weeks after 
commencement (1, 2). 
Despite current guidance, many patients with PMR are unable to stop their steroids within this time-
frame. Observational data from the  US in 1980s showed that around 40% of patients with PMR 
were able to stop their steroids in a mean time of 95 weeks, yet it was estimated that another 40% 
would continue steroids for longer than 4 years (4).  The median duration of steroid therapy has also 
been increasing year on year within the UK. The Health Improvement Network (THIN) includes data 
from UK adult patients registered with contributing general practices between January 1989 and 
December 2008 (5). In 1991 the median duration of steroid therapy for men with PMR/GCA was 
men was 53 weeks (28.4, 126.1) and 58 weeks (CI 95% 28.4, 122.9) for women; by 2005 it had 
reached 56.7 weeks in men (33.6, 101) and 63.7 weeks (32.3, 128.3) in women (5). 
These data suggest that there is a reluctance to discontinue steroids in patients with PMR. This high 
prevalence of long-term steroid use in this group of patients is a particular concern because of the 
increasing awareness of the risks associated with steroids even at what might have hitherto been 
regarded as safe ‘physiological’ doses. 
Cumulative steroid exposure is strongly related to the well-recognised adverse effects including: eye 
related morbidity (cataracts, glaucoma), cardiovascular risk factors (hypertension, diabetes), 
increased risk for infections and fragility fractures (6). A Task Force endorsed by the European 
League Against Rheumatism (EULAR) produced recommendations for steroid therapy in rheumatic 
diseases. The systematic review of 18 studies revealed the following adverse event rate per 100 
patient years of follow-up: eye morbidity (cataracts, glaucoma) 4/100, cardiovascular morbidity 
(dyslipidaemia, oedema and electrolyte imbalance, renal and heart dysfunction, hypertension) 
15/100, endocrine morbidity (glucose intolerance and diabetes, fat redistribution, hormone 
dysregulation) 7/100, infections (viral, bacterial, skin) 15/100 and musculoskeletal morbidity 
(osteoporosis, osteonecrosis, myopathy) 4/100 (6).  
Oral steroids remain the leading cause of hypothalamic-pituitary-adrenal (HPA) dysfunction (7). No 
study has investigated the burden of HPA dysfunction in patients with PMR, however a study was 
performed in those with the related condition of Giant Cell Arteritis. Nevertheless, in a study of 150 
patients with GCA, 49% of patients were considered non-responders to a Short-Synacthen test 
(ACTH) (8). Of these 85% recovered normal adrenal function within 36 months, however 5% never 
recovered their adrenal function (8). The main predictive factors were total dose and duration of 
steroid therapy (> 8.5 g steroid and > 76 weeks treatment course). It is likely that patients with GCA 
receive higher initial starting doses, and have greater cumulative steroid dosages than patients with 
PMR. 
Knowledge of HPA dysfunction is important not least so as the patient can be appropriately 
managed. In 1952 a patient developed circulatory shock following withdrawal of their steroids prior 
to surgery (9). Since then guidelines have been produced, with patients receiving greater than 10 mg 
of steroid needing perioperative cover with additional steroids (10). Perhaps this pragmatic-focus 
based purely on the dose of steroids has led to the disinterest in ascertaining the prevalence of HPA 
dysfunction in patients with PMR on long-term, low-dose steroids. However it is plausible that 
patients with PMR, even on doses lower than 10 mg daily, have HPA dysfunction.  
Currently there is insufficient evidence to inform clinicians on how best to manage the withdrawal of 
steroids in patients with PMR that are in remission on treatment. The slow withdrawal of steroids at 
a rate of 1 mg daily each month that has become enshrined in clinical practice and national 
guidelines has an empirical basis. The guidance for PMR needs to be refined, and should take into 
account an assessment of adrenal function in all patients on long-term steroids.  
In summary, prescriptions for long-term steroids in patients with PMR are increasing, suggesting that 
there are important barriers to the implementation of current guidance in clinical practice and 
raising significant concerns over harm.  Advice on steroid withdrawal in PMR needs to be backed by 
much more sound evidence on the true risk of flare, together with sound knowledge of the rate of 
hypoadrenalism in this patient group.  Rheumatologists and general practitioners need to be wary of 
the patients who are in remission and yet maintained on long-term steroids.  
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